New hope for Tough-to-Treat leukemia: drug combo trial targets High-Risk cases
NCT ID NCT06253637
Summary
This trial is testing whether adding the drug daratumumab to standard chemotherapy can help more adults with very high-risk T-cell acute lymphoblastic leukemia (T-ALL) achieve deep remission. The study will enroll 31 adults aged 18-65 with specific high-risk features. Researchers aim to see if this combination increases the number of patients with no detectable cancer after the first round of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-LYMPHOCYTIC LEUKEMIA, ACUTE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ematologia AOU Careggi
Florence, Italy
-
Ematologia AOU Policlinico Umberto I
Roma, Italy
-
Ematologia P.O. Vito Fazzi - Lecce
Lecce, Italy
Conditions
Explore the condition pages connected to this study.